FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022183879> ?p ?o ?g. }

• W2022183879 endingPage "8229" @default.
• W2022183879 startingPage "8225" @default.
• W2022183879 abstract "Human deoxyribonuclease I (DNase I), an enzyme recently approved for treatment of cystic fibrosis (CF), has been engineered to create two classes of mutants: actin-resistant variants, which still catalyze DNA hydrolysis but are no longer inhibited by globular actin (G-actin) and active site variants, which no longer catalyze DNA hydrolysis but still bind G-actin. Actin-resistant variants with the least affinity for actin, as measured by an actin binding ELISA and actin inhibition of [33P] DNA hydrolysis, resulted from the introduction of charged, aliphatic, or aromatic residues at Ala-114 or charged residues on the central hydrophobic actin binding interface at Tyr-65 or Val-67. In CF sputum, the actin-resistant variants D53R, Y65A, Y65R, or V67K were 10-to 50-fold more potent than wild type in reducing viscoelasticity as determined in sputum compaction assays. The reduced viscoelasticity correlated with reduced DNA length as measured by pulsed-field gel electrophoresis. In contrast, the active site variants H252A or H134A had no effect on altering either viscoelasticity or DNA length in CF sputum. The data from both the active site and actin-resistant variants demonstrate that the reduction of viscoelasticity by DNase I results from DNA hydrolysis and not from depolymerization of filamentous actin (F-actin). The increased potency of the actin-resistant variants indicates that G-actin is a significant inhibitor of DNase I in CF sputum. These results further suggest that actin-resistant DNase I variants may have improved efficacy in CF patients." @default.
• W2022183879 created "2016-06-24" @default.
• W2022183879 creator A5000440821 @default.
• W2022183879 creator A5016517297 @default.
• W2022183879 creator A5027714172 @default.
• W2022183879 creator A5035059847 @default.
• W2022183879 creator A5048822826 @default.
• W2022183879 creator A5048859997 @default.
• W2022183879 creator A5069498671 @default.
• W2022183879 creator A5081878988 @default.
• W2022183879 date "1996-08-06" @default.
• W2022183879 modified "2023-10-13" @default.
• W2022183879 title "Engineering actin-resistant human DNase I for treatment of cystic fibrosis." @default.
• W2022183879 cites W1482074366 @default.
• W2022183879 cites W1503658815 @default.
• W2022183879 cites W1538805645 @default.
• W2022183879 cites W157365346 @default.
• W2022183879 cites W1595624904 @default.
• W2022183879 cites W1786021994 @default.
• W2022183879 cites W185581733 @default.
• W2022183879 cites W1892403664 @default.
• W2022183879 cites W1995997366 @default.
• W2022183879 cites W1997182007 @default.
• W2022183879 cites W2006773867 @default.
• W2022183879 cites W2010133677 @default.
• W2022183879 cites W2023546954 @default.
• W2022183879 cites W2028171116 @default.
• W2022183879 cites W2035194855 @default.
• W2022183879 cites W2054819126 @default.
• W2022183879 cites W2056671887 @default.
• W2022183879 cites W2058497997 @default.
• W2022183879 cites W2074964546 @default.
• W2022183879 cites W2076015841 @default.
• W2022183879 cites W2090126338 @default.
• W2022183879 cites W2112787865 @default.
• W2022183879 cites W2117541941 @default.
• W2022183879 cites W2138270253 @default.
• W2022183879 cites W2140040046 @default.
• W2022183879 cites W2147562836 @default.
• W2022183879 cites W2150399236 @default.
• W2022183879 cites W2153495209 @default.
• W2022183879 cites W2239393952 @default.
• W2022183879 cites W2333398204 @default.
• W2022183879 cites W2336714143 @default.
• W2022183879 cites W2888511473 @default.
• W2022183879 cites W4290764291 @default.
• W2022183879 doi "https://doi.org/10.1073/pnas.93.16.8225" @default.
• W2022183879 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/38651" @default.
• W2022183879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8710851" @default.
• W2022183879 hasPublicationYear "1996" @default.
• W2022183879 type Work @default.
• W2022183879 sameAs 2022183879 @default.
• W2022183879 citedByCount "77" @default.
• W2022183879 countsByYear W20221838792012 @default.
• W2022183879 countsByYear W20221838792013 @default.
• W2022183879 countsByYear W20221838792014 @default.
• W2022183879 countsByYear W20221838792016 @default.
• W2022183879 countsByYear W20221838792017 @default.
• W2022183879 countsByYear W20221838792018 @default.
• W2022183879 countsByYear W20221838792019 @default.
• W2022183879 countsByYear W20221838792020 @default.
• W2022183879 countsByYear W20221838792021 @default.
• W2022183879 countsByYear W20221838792022 @default.
• W2022183879 countsByYear W20221838792023 @default.
• W2022183879 crossrefType "journal-article" @default.
• W2022183879 hasAuthorship W2022183879A5000440821 @default.
• W2022183879 hasAuthorship W2022183879A5016517297 @default.
• W2022183879 hasAuthorship W2022183879A5027714172 @default.
• W2022183879 hasAuthorship W2022183879A5035059847 @default.
• W2022183879 hasAuthorship W2022183879A5048822826 @default.
• W2022183879 hasAuthorship W2022183879A5048859997 @default.
• W2022183879 hasAuthorship W2022183879A5069498671 @default.
• W2022183879 hasAuthorship W2022183879A5081878988 @default.
• W2022183879 hasBestOaLocation W20221838791 @default.
• W2022183879 hasConcept C125705527 @default.
• W2022183879 hasConcept C130861313 @default.
• W2022183879 hasConcept C142669718 @default.
• W2022183879 hasConcept C1491633281 @default.
• W2022183879 hasConcept C153911025 @default.
• W2022183879 hasConcept C185592680 @default.
• W2022183879 hasConcept C2779377703 @default.
• W2022183879 hasConcept C2993400109 @default.
• W2022183879 hasConcept C3017666073 @default.
• W2022183879 hasConcept C552990157 @default.
• W2022183879 hasConcept C55493867 @default.
• W2022183879 hasConcept C80722340 @default.
• W2022183879 hasConcept C86803240 @default.
• W2022183879 hasConceptScore W2022183879C125705527 @default.
• W2022183879 hasConceptScore W2022183879C130861313 @default.
• W2022183879 hasConceptScore W2022183879C142669718 @default.
• W2022183879 hasConceptScore W2022183879C1491633281 @default.
• W2022183879 hasConceptScore W2022183879C153911025 @default.
• W2022183879 hasConceptScore W2022183879C185592680 @default.
• W2022183879 hasConceptScore W2022183879C2779377703 @default.
• W2022183879 hasConceptScore W2022183879C2993400109 @default.
• W2022183879 hasConceptScore W2022183879C3017666073 @default.
• W2022183879 hasConceptScore W2022183879C552990157 @default.
• W2022183879 hasConceptScore W2022183879C55493867 @default.

• next